Study details
Enrolling now
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Baptist Health South Florida
NCT IDNCT05554302ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
20
Study length
about 7.1 years
Ages
18+
Locations
1 site in FL
What this study is about
Researchers are testing a new imaging agent, 18F-Fluciclovine, to see if it can help doctors better evaluate brain tumors after surgery. The trial will involve patients who have had brain metastasis removed and are scheduled for stereotactic radiosurgery (SRS).
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 18F-Fluciclovine
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
fluciclovine (18F)
Endpoints
Primary: Change in PET scan standardized uptake value (SUV) parameters